Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA42BV)

• Drug Name: AVE-2268 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 10068465
  TTD Drug ID: DMA42BV

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium/glucose cotransporter 2 (SGLT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dapagliflozin	DM28UJG	Non-insulin dependent diabetes	5A11	Approved	[3]
Empagliflozin	DMRF9YK	Type-1 diabetes	5A10	Approved	[3]
Canagliflozin	DMFRM1I	Non-insulin dependent diabetes	5A11	Approved	[4]
PF-04971729	DM79VXT	Type-2 diabetes	5A11	Approved	[5]
Sotagliflozin	DMMLXA9	Heart failure	BD10-BD13	Approved	[6]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[7]
ASP1941	DMGQ1TV	Liver disease	DB90-BD99	Phase 3	[8]
Remogliflozin etabonate	DMW4YK1	Type-1/2 diabetes	5A10-5A11	Phase 2	[9]
LIK-066	DM32NWD	Heart failure	BD10-BD13	Phase 2	[10]
YM-543	DMRZBPI	Type-2 diabetes	5A11	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium/glucose cotransporter 2 (SGLT2)	TTLWPVF	SC5A2_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT00361738) Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment. U.S. National Institutes of Health.
• [2] Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [5] Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8.
• [6] LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocr Res. 2013 Aug;38(3):168-183.